Viatris and the presbyopia drug race: What ASCRS 2026 data means for the MR-141 FDA decision in October

The pharmacological treatment of presbyopia, a condition that affects the near vision of roughly 128 million Americans over the age of 45, has moved from a largely ignored corner of ophthalmic therapeutics into one of the most actively contested pipeline spaces in US pharmaceutical development. At the American Society of Cataract and Refractive Surgery Annual Meeting in Washington DC this week, Viatris Inc. (Nasdaq: VTRS) is presenting the full results of its VEGA-3 Phase 3 trial for MR-141, its phentolamine ophthalmic solution 0.75%, in front of the anterior segment surgery community. The presentation is the latest step in a regulatory timeline that ends with an FDA decision expected on October 17, 2026. For investors and industry observers, the Washington DC data readout is a staging post on the way to that decision, and it arrives in a market that has changed significantly in the past two years.

What is presbyopia and why has it become a major pharmaceutical target now?

Presbyopia is the gradual loss of the ability to focus on close objects that results from the natural stiffening of the crystalline lens with age. The condition typically becomes noticeable in the early to mid-40s and is nearly universal: by age 50, most adults in the United States require some form of near-vision correction. The Cleveland Clinic has estimated there will be approximately 2.1 billion cases of presbyopia globally by 2030, up from 1.8 billion in 2015. In the United States alone, market estimates put the diagnosed prevalent patient pool at approximately 110 million in 2024, with the number growing steadily on the back of ageing demographics. For most of its history, presbyopia was managed exclusively through reading glasses, bifocals, contact lenses, or surgical procedures including presbyopia-correcting IOL implants. The development of prescription eye drops as a non-invasive daily-use alternative is a relatively recent phenomenon, and the category only became commercially real when AbbVie’s Vuity, a pilocarpine HCl 1.25% solution, received FDA approval in October 2021.

What is MR-141 and how does it differ from the pilocarpine-based drops already on the market?

MR-141 is phentolamine ophthalmic solution 0.75%, a preservative-free topical eye drop developed under a global licensing arrangement between Opus Genetics (Nasdaq: IRD) and Viatris, which holds exclusive US commercialisation rights. The drug’s mechanism of action distinguishes it from the pilocarpine-based products that currently dominate the approved market. Pilocarpine works as a cholinergic muscarinic agonist, stimulating the iris sphincter and ciliary body to constrict the pupil and improve near vision, but the ciliary muscle engagement can cause side effects including headache, brow ache, and a slight myopic shift that temporarily blurs distance vision. Phentolamine takes a different physiological route: it is a nonselective alpha-1 and alpha-2 adrenergic antagonist that reduces pupil size by blocking alpha-1 receptors on the iris dilator muscle rather than stimulating the ciliary body. The developers argue this sympatholytic approach preserves distance vision more effectively because it avoids ciliary muscle engagement altogether. Opus Genetics’ chief executive George Magrath has described the drug as working by modulating the iris to support a smaller pupil in a controlled functional range, with a sustained effect on pupil diameter of up to 20 hours.

This is also the same compound already approved in the United States under the brand name Ryzumvi, where it is indicated for reversing pharmacologically induced mydriasis. That existing approval provides Viatris with a regulatory and commercial precedent. The supplemental new drug application filed with the FDA for the presbyopia indication is an sNDA rather than a full NDA, which represents a meaningful procedural advantage in the review process.

What did the VEGA-3 trial find and what is being presented at ASCRS 2026?

The VEGA-3 trial is the second of two pivotal Phase 3 studies supporting the sNDA filing. It was a randomised, double-blind, placebo-controlled study enrolling 545 patients who were randomised in a 3:2 ratio to receive either MR-141 or placebo once daily in the evening. The primary endpoint was the percentage of patients achieving a gain of three or more lines in binocular distance-corrected near visual acuity without losing five or more letters of binocular best-corrected distance visual acuity at 12 hours post-dose on Day 8. The top-line results, announced by Viatris in June 2025, showed that 27.2 percent of patients in the MR-141 arm achieved the primary endpoint compared with 11.5 percent in the placebo group, a statistically significant difference with a p-value below 0.0001. The safety profile was consistent with prior phentolamine trials, with no serious treatment-related adverse events. The most common reported side effects were conjunctival hyperemia, instillation site irritation, and dysgeusia. The full data from VEGA-3, including the detail that clinicians and regulators will scrutinise beyond the top-line release, are being presented at ASCRS 2026 this week and will also appear at the Association for Research in Vision and Ophthalmology meeting in Denver in May.

Viatris and Opus Genetics are jointly hosting an independent educational symposium on Saturday evening, April 11, at the Westin DC Downtown in Washington. The symposium, titled “Presbyopia Re-Envisioned: A New Era of Pharmacological Vision Correction,” is hosted by PRIME, a continuing medical education platform, and is designed to foster clinician-to-clinician discussion around the evolving management of the condition ahead of the anticipated FDA decision.

How competitive is the presbyopia eye drop market that MR-141 would be entering?

The market that MR-141 would enter if approved in October 2026 looks markedly different from the one that existed when the VEGA programme began. In early 2025, Orasis Pharmaceuticals commercially launched Qlosi, pilocarpine HCl 0.4%, the second approved presbyopia drop to reach the US market. In July 2025, LENZ Therapeutics received FDA approval for Vizz, an aceclidine ophthalmic solution 1.44% that represents the first approval of a novel miotic agent for presbyopia in the United States. Aceclidine is not a new molecule, but it has not previously been approved in the US, and Vizz’s Phase 3 data showed efficacy onset within 30 minutes and a duration of up to 10 hours across more than 30,000 treatment days of safety data. Tenpoint Therapeutics submitted an NDA for Brimochol PF, a fixed-combination carbachol 2.75% and brimonidine tartrate 0.1% preservative-free solution, with a decision expected in the first half of 2026.

The category’s originator, Vuity, has faced adoption headwinds since its 2021 approval, with clinicians reporting patient hesitation around side effects including redness and headache during an initial adjustment period, and a concern about the rare association between pilocarpine use and retinal complications that has made some practitioners cautious about prescribing. These market dynamics create space for a mechanistically differentiated product like MR-141, but also mean that by the time phentolamine reaches the market, ophthalmologists and optometrists will already have established prescribing patterns around two or three other approved drops.

Viatris is also presenting additional data at ASCRS 2026 beyond the VEGA-3 readout. The company’s four-abstract slate includes results from a Phase 1 study of varenicline solution nasal spray in healthy Japanese adults, a post-hoc analysis of MIRA-2 examining the optical impact of Ryzumvi for reversing pharmacologically induced mydriasis, and an encore presentation of LYNX-2, a Phase 3 study evaluating MR-142, also phentolamine ophthalmic solution 0.75%, for visual disturbances in low-light conditions in post-refractive surgery patients. The LYNX-2 data broadens the commercial story for phentolamine beyond presbyopia into a distinct patient population of approximately 800,000 post-refractive surgery patients annually in the United States who experience night vision disturbances in dim light.

What is the FDA review status and what happens next for Viatris and MR-141?

The FDA accepted the Viatris sNDA for MR-141 for review in February 2026 and assigned a PDUFA goal date of October 17, 2026. That date sets the regulatory clock for the remainder of the year and establishes the earliest plausible US commercial launch window for phentolamine in the presbyopia indication. Both pivotal trials, VEGA-2 and VEGA-3, met the primary and all key secondary endpoints and reported no treatment-related serious adverse events, giving the filing a clean efficacy and safety data package. The sNDA structure, building on an already-approved drug with an established US manufacturing and distribution footprint through Ryzumvi, reduces some of the logistical risks that typically accompany a first-in-class launch. Viatris has guided that it intends to pursue international markets on a phased schedule, with an EU launch expected to follow the US and a Japan timeline further out, reflecting the established regulatory sequencing for ophthalmic pharmaceutical products of this type.

For investors in Viatris (VTRS) and Opus Genetics (IRD), the October PDUFA date is the next material catalyst after the ASCRS data presentation. Viatris is a large-cap generics and branded pharmaceutical company trading on Nasdaq with a broad global portfolio, and the MR-141 programme represents a relatively contained revenue opportunity within a larger business. Opus Genetics, by contrast, is a clinical-stage company where the phentolamine licensing arrangement sits alongside an AAV gene therapy pipeline for inherited retinal diseases, meaning the commercial success of MR-141 in the US carries proportionally greater weight for the smaller company’s financial position. Both companies have signalled confidence in the regulatory outcome, though standard pharmaceutical development risks apply and FDA review outcomes are not guaranteed.

The broader market context is supportive of the category. The global presbyopia treatment market was valued at approximately US$10.17 billion in 2024 across all treatment modalities, including glasses, contact lenses, surgical options, and pharmacological products, and is projected to grow at a compound annual rate of around 5.5 percent through 2033. Within that total, the pharmacological segment is growing from a very low base established by Vuity in 2021 and now has multiple approved products competing for prescription share. What the ASCRS 2026 presentations this week will contribute to that picture is a more granular clinical data set that ophthalmologists across the United States can evaluate before the FDA issues its October decision.